Predicting MEK Inhibitor Response in Lung Cancer: A Proper Signature Is Required.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 27923842.
- Also identified by DOI 10.1158/1078-0432.CCR-16-2576.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The ERK signaling pathway is one of the most commonly deregulated pathways in cancer. Assays that accurately measure ERK signaling output in clinical specimens would be extremely helpful not only in determining the pharmacodynamic effects of drug treatment but also in selecting those patients most likely to respond to therapy. <i>Clin Cancer Res; 23(6); 1365-7. ©2016 AACR</i><i>See related article by Brant et al., p. 1471</i>.
Medical subject headings
- Lung Neoplasms
- MAP Kinase Signaling System
- Protein Kinase Inhibitors